{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"23","upperLimit":"1549","value":"200"},{"groupId":"OG001","lowerLimit":"13","upperLimit":"2987","value":"255.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"title":"CD3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8","upperLimit":"626","value":"73"},{"groupId":"OG001","lowerLimit":"4","upperLimit":"1186","value":"81"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"43"}],"units":"Participants"}],"title":"CD4"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8","upperLimit":"1170","value":"104"},{"groupId":"OG001","lowerLimit":"4","upperLimit":"2529","value":"151"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"43"}],"units":"Participants"}],"title":"CD8"}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"43"}],"units":"Participants"}],"description":"A descriptive comparison of the median number of T-cells (CD3, CD4, CD8) between treatment arms (single vs. tandem myeloablative regimens) will be performed.","dispersionType":"Full Range","groups":[{"description":"Induction therapy + single myeloablative consolidation","id":"OG000","title":"Single HST (CEM)"},{"description":"Induction therapy + tandem myeloablative consolidation","id":"OG001","title":"Tandem HST (CEM), Randomly Assigned"}],"paramType":"MEDIAN","populationDescription":"All eligible patients that had CD3, CD4 and CD8T-cell count evaluated at the end of reporting period 3.","reportingStatus":"POSTED","timeFrame":"Up to 6 months after completion of assigned myeloablation therapy","title":"Enumeration of Peripheral Blood Cluster of Differentiation (CD)3, CD4, and CD8 Cells","type":"SECONDARY","unitOfMeasure":"cells/mm^3"}